New Year, new approach to weight loss: Almost three quarters of UK women are considering using GLP-1s in 2025

As 2024 draws to a close, the new year ushers in the opportunity to set new goals for the year ahead. While weight-loss and fitness are staples of New Year resolutions they are commonly known to be the unsustainable resolutions that don’t continue past January.

Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe – Biotech Investments

Biophytis / Key word(s): Miscellaneous Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe 08-Aug-2023 / 07:00 CET/CEST

August 9, 2023

Depression TMS Cleared for Teens; Phase III Narcolepsy Win; Fake ADHD Diagnosis?

Neuronetics said the FDA cleared its transcranial magnetic stimulation (TMS) device, NeuroStar, as an adjunct therapy for the first-line treatment of major depressive disorder in

March 28, 2024

Innovative sweat monitoring device enables non-invasive health monitoring

Sweat contains biomarkers that can monitor various health conditions, from diabetes to genetic disorders. Sweat sampling, unlike blood collection, is preferred by users due to

May 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.